487 related articles for article (PubMed ID: 16978743)
21. Pathogenesis of Parkinson's disease.
Sherer TB; Betarbet R; Greenamyre JT
Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
[TBL] [Abstract][Full Text] [Related]
22. Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein.
Ito S; Nakaso K; Imamura K; Takeshima T; Nakashima K
Neurosci Res; 2010 Jan; 66(1):124-30. PubMed ID: 19835916
[TBL] [Abstract][Full Text] [Related]
23. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
24. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
Chiba-Falek O; Lopez GJ; Nussbaum RL
Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
[TBL] [Abstract][Full Text] [Related]
25. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Prigione A; Piazza F; Brighina L; Begni B; Galbussera A; Difrancesco JC; Andreoni S; Piolti R; Ferrarese C
Neurosci Lett; 2010 Jun; 477(1):6-10. PubMed ID: 20399833
[TBL] [Abstract][Full Text] [Related]
26. Over-expression of α-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone.
Ma KL; Yuan YH; Song LK; Han N; Chen NH
Neurosci Lett; 2011 Mar; 491(2):148-52. PubMed ID: 21238542
[TBL] [Abstract][Full Text] [Related]
27. Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation.
Battisti C; Formichi P; Radi E; Federico A
J Neurol Sci; 2008 Apr; 267(1-2):120-4. PubMed ID: 18061619
[TBL] [Abstract][Full Text] [Related]
28. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death.
Kaul S; Anantharam V; Kanthasamy A; Kanthasamy AG
Brain Res Mol Brain Res; 2005 Sep; 139(1):137-52. PubMed ID: 15978696
[TBL] [Abstract][Full Text] [Related]
29. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
30. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
[TBL] [Abstract][Full Text] [Related]
32. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
Halliday GM; McCann H
Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
[TBL] [Abstract][Full Text] [Related]
33. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.
Orth M; Tabrizi SJ; Tomlinson C; Messmer K; Korlipara LV; Schapira AH; Cooper JM
Neurochem Int; 2004 Oct; 45(5):669-76. PubMed ID: 15234109
[TBL] [Abstract][Full Text] [Related]
34. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
Park SS; Lee D
Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
[TBL] [Abstract][Full Text] [Related]
35. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
36. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
Häbig K; Walter M; Stappert H; Riess O; Bonin M
Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
[TBL] [Abstract][Full Text] [Related]
37. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
[TBL] [Abstract][Full Text] [Related]
38. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
39. Genetic contributions to Parkinson's disease.
Huang Y; Cheung L; Rowe D; Halliday G
Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between alpha-synuclein and Parkinson's disease].
Nishioka K; Hattori N
Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]